Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP15 | Q460N3 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | PARG | Q86W56 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029258 | 0.87 | PARP10 (0.54) | PARP15PARP10TNKS2PARP2PDE3B | |
| SCHEMBL7031912 | 0.84 | CA12 (0.46) | PARP15PARP10TNKS2PARP2PDE3B | |
| SCHEMBL7029487 | 0.84 | CA12 (0.46) | PARP15PARP10TNKS2PARP2PDE3B | |
| SCHEMBL7024662 | 0.83 | PDE3B (0.53) | PDE3BPDE3ACA12CA9ALDH1A1 | |
| SCHEMBL3124589 | 0.81 | ALDH1A1 (0.63) | CA12CA9ALDH1A1KDM4EHPGD | |
| SCHEMBL7029314 | 0.81 | PDE3B (0.43) | PARP15PARP10TNKS2PARP2PDE3B | |
| SCHEMBL7028358 | 0.79 | HTR1D (0.48) | PDE3BPDE3ACA12CA9ALDH1A1 | |
| SCHEMBL7027645 | 0.79 | HTR1A (0.50) | PDE3BPDE3ACA12CA9ALDH1A1 | |
| SCHEMBL7027727 | 0.78 | PDE3B (0.46) | PDE3BPDE3ACA12CA9ALDH1A1 | |
| SCHEMBL7029183 | 0.77 | KIF11 (0.50) | PDE3BPDE3ACA12CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC | 2020-02-13 | — | — | US | disclosed |
| WO-2010127208-A1 | INHIBITORS OF ACETYL-COA CARBOXYLASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-04 | — | — | WO | disclosed |
| EP-0878468-B1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| EP-0775697-B1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL CO (JP) | 2003-02-12 | — | — | EP | disclosed |
| US-5994542-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-11-30 | — | — | US | disclosed |
| EP-0878468-A1 | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5756738-A | Process for producing 1-substituted tetrahydroquinazolines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-05-26 | — | — | US | disclosed |
| EP-0775697-A1 | Process for producing 1-substituted tetrahydroquinazolindionen | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071735-B2 | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors | SLC2A3, SLC2A4, SLC2A1 | PARP15 2730/4885PARP10 2576/4885TNKS2 4500/4885 |
| US-20200046702-A1 | TREATMENT OF INFLAMMATORY CONDITIONS AND AUTOIMMUNE DISEASES WITH GLUCOSE UPTAKE INHIBITORS | SLC2A3, SLC2A4, SLC2A1 | PARP15 2730/4885PARP10 2576/4885TNKS2 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.